Johnson & Johnson reported Phase 3 results showing Tecvayli (a dual‑targeting T‑cell engager) produced a large survival and progression benefit in relapsed multiple myeloma. In the MajesTEC‑9 trial J&J randomized 614 patients and reported a substantial reduction in risk of progression or death compared with established regimens, prompting regulator engagement and plans to discuss label expansion. The company framed the readout as validation for moving Tecvayli into earlier lines of therapy and flagged further regulatory interactions.